Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

This study is looking at the safety and tolerability of a three-in-one inhaler called Breztri Aerosphere (which combines budesonide, glycopyrrolate, and formoterol) in Indian patients with chronic obstructive pulmonary disease (COPD) — a long-term lung condition that makes it hard to breathe. This is a post-marketing study, meaning the drug is already approved and researchers want to gather real-world safety data in India. **You may be eligible if...** - You have a confirmed diagnosis of COPD from a doctor - You have had at least one severe COPD flare-up or two moderate ones in the past year - Your lung function test (FEV1) is between 30% and 80% of expected - You are male or female and not pregnant or breastfeeding - You are post-menopausal or using effective contraception **You may NOT be eligible if...** - You have had a moderate or severe COPD flare-up in the last 6 weeks - You are pregnant, breastfeeding, or planning to become pregnant - You have had an allergic reaction to similar medications - You are currently in another interventional clinical trial - You have serious other health conditions that might put you at risk Talk to your doctor to see if this trial is right for you.